Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing

Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.

April 11, 2025

Vol.51 No.14

By Claire Marie Porter

Clinical Roundup

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Families facing a childhood cancer diagnosis experience a range of psychological, social, and emotional stressors, from anxiety to financial strain to sibling concerns.

April 11, 2025

Vol.51 No.14

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

In Brief

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Nemours Children’s Health opened the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, on March 19. The institute is a state-of-the-art facility for pediatric patients in the Delaware Valley and beyond.

March 21, 2025

Vol.51 No.11

Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

YOU MAY BE INTERESTED IN

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Renew today!

Subscriber content

Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

YOU MAY BE INTERESTED IN

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s MercyWhistleblower lawsuit alleges wrongful firing

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing